Calcium ion (Ca 2ϩ ) regulates many important physiological processes including gene expression, neuronal synaptic plasticity, and cell death (1) . The effects of changes in intracellular Ca 2ϩ levels are mediated primarily by Ca 2ϩ -binding proteins that belong to the EF-hand superfamily (2, 3) . The recoverin subgroup includes neuronal calcium sensors such as recoverin (4) , neurocalcin (5) , and frequenin (6) , all of which are Nmyristoylated and possess four EF-hand motifs (7) (Fig. 1) . A characteristic feature of the recoverin family is the sequence CPXG that prevents the binding of Ca 2ϩ to the first EF-hand. Recently, a new member of the recoverin family variously named calsenilin (8) , DREAM 1 (9) , and KChIP3 (10) has been identified in the human brain and reported to have several biological functions.
Calsenilin was first identified by the yeast two-hybrid system to interact with the C-terminal 40 residues of presenilin 2, a membrane protein genetically linked to Alzheimer's disease (8) . Calsenilin consists of 256 amino acids, and the C-terminal 190 residues are about 40% identical in amino acid sequence to frequenin, a representative protein of the recoverin family ( Fig.  1) . Recently, it has been reported that calsenilin reverses the presenilin-mediated enhancement of Ca 2ϩ signaling (11) and that calsenilin is a substrate for caspase-3 that also interacts with the C-terminal region of presenilin 2 (12) .
The protein named DREAM was reported as the first Ca 2ϩ -regulated transcriptional repressor (9) . DREAM represses the transcription of human prodynorphin and c-fos genes in the brain by binding to the DRE only in the absence of calcium and derepresses the transcription at high Ca 2ϩ levels. DREAM also binds to a silencer sequence in the 3Ј-untranslated region of the apoptotic gene hrk and represses the expression of downstream reporter genes (13) . The human DREAM protein was originally reported to consist of 284 residues (9) , in which the C-terminal 256 residues are identical to calsenilin. A more recent study has revealed that the C-terminal 256 residues of DREAM are sufficient for the calcium-regulated transcriptional repression (14, 15) . However, the precise length of the endogenous DREAM protein (284 versus 256 residues) is still not known, and it is still unclear how DREAM recognizes the different DRE sequences of prodynorphin and c-fos.
The potassium channel-interacting proteins KChIP1 and KChIP2 were identified by the yeast two-hybrid system to interact with the N-terminal 180 residues of A-type voltagegated potassium (Kv4.2) channels (10) . KChIP1 and KChIP2 also bind to intact Kv4.2 channels and activate channel kinetics only at high Ca 2ϩ levels. Notably, the N-terminal 70 residues of KChIP1 and KChIP2 do not contribute significantly to the modulation of Kv4.2 channels. Interestingly, KChIP1 and KChIP2 are more than 70% identical in sequence to calsenilin (Fig. 1) , and calsenilin was also shown to interact with Kv4.2 channels. Hence, calsenilin is also referred to as KChIP3.
The single protein variously named calsenilin, DREAM, and KChIP3 appears to possess multiple functions in different compartments of the cell by regulating completely different target molecules. Calsenilin binds and regulates presenilin proteins in the endoplasmic reticulum, calcium-free DREAM binds to DRE sequences of DNA in the cell nucleus, and calcium-bound KChIP3 may bind and activate Kv4.2 channels on the plasma membrane. Therefore, it is of particular interest to learn how this one protein can bind and recognize several different target molecules. Here we report the physicochemical characterization of the multifunctional protein calsenilin/DREAM/KChIP3 (referred to hereafter as DREAM) as an important step toward understanding its various mechanisms of target recognition. Furthermore, we have characterized the novel DNA binding properties of this protein, and we suggest a possible mechanism for Ca 2ϩ -regulated gene expression.
EXPERIMENTAL PROCEDURES
Expression and Purification of Human Calsenilin/DREAM/ KChIP3-The coding sequence of human calsenilin/DREAM/KChIP3 was amplified by polymerase chain reaction from a mammalian expression vector (pcDNA3.1) containing calsenilin/DREAM cDNA using the primers 5Ј-CTAGGCCTCATATGCAGCCGGCTAAGGAAG-3Ј and 5Ј-CTAGGCCTCTCGAGGATGACATTCTCAAAC-3Ј. The resulting product was ligated into pET-22b(ϩ) (Novagen) using the sites for NdeI and XhoI. The sequence was verified by sequencing.
After the transformation of the construct into Escherichia coli BL21 (DE3) (Stratagene), the calsenilin/DREAM/KChIP3 protein with a 6ϫHis tag at the C terminus was overexpressed as inclusion bodies. Strains were grown in 2 liters of LB media with 100 g/ml ampicillin at 37°C. When the optical density of the culture at 600 nm had reached 0.8, isopropyl-1-thio-␤-D-galactopyranoside was added to the culture to a final concentration of 0.7 mM, and the culture was further incubated for 3.5 h at 37°C. Cells were harvested by centrifugation, resuspended in lysis buffer (20 mM Tris-HCl, pH 8.0, 0.1 M KCl, 10% (v/v) glycerol, 1 mM ␤-mercaptoethanol, and 0.1 mM phenylmethylsulfonyl fluoride), and disrupted by French press at 900 p.s.i. Disruption by French press was repeated once. Cell debris and inclusion bodies were collected by centrifugation. The pellet was suspended in wash buffer (1.0% (v/v) Triton X-100 in the lysis buffer), homogenized, and sonicated, and the insoluble material was collected by centrifugation. This wash was repeated three times. The pellet from the last wash was suspended in guanidine buffer (6 M guanidine-HCl, 0.1 M sodium phosphate, 10 mM Tris-HCl, pH 8.0, and 1 mM ␤-mercaptoethanol), homogenized, and incubated for 15 min at room temperature. After centrifugation to remove insoluble material, the supernatant was applied onto a Talon (CLONTECH) column previously equilibrated in the guanidine buffer. After washing the column with the guanidine buffer, the protein was eluted with imidazole buffer (0.1 M imidazole in the guanidine buffer). The eluted solution was dialyzed versus refolding buffer (10 mM TrisHCl, pH 7.4, 0.3 M NaCl, 10% (v/v) glycerol, 0.1 M EDTA, and 1 mM DTT) for 24 h. Then, 10 mM lauryldimethylamine oxide (LDAO) was added to the sample, which was dialyzed versus LDAO buffer (10 mM Tris-HCl, pH 7.4, 10 mM LDAO, 1 mM EDTA, and 1 mM DTT). The sample was applied onto a DEAE column previously equilibrated in the LDAO buffer, and then it was eluted with NaCl gradient (0 -0.3 M NaCl over 3 h at 2 ml/min). Further purification of DREAM was achieved using a size exclusion column (S-300 HR) with the LDAO buffer.
Expression and Purification of Mouse DREAM and Deletion Mutants-Genes encoding mouse DREAM and its deletion mutants (residues 1-70, mut1-70; residues 1-96, mut1-96; residues 65-256, mut65-256) were inserted into pET15b (Novagen) expression vectors. These constructs were transformed into E. coli BL21 (DE3) (Stratagene) cells and grown in 2 liters of LB media with 100 g/ml ampicillin at 37°C. After the induction with 0.7 mM isopropyl-1-thio-␤-D-galactopyranoside, cultures were incubated for another 3 h. Cells were harvested by centrifugation and resuspended in buffer A (20 mM Tris-HCl, pH 8.0, 20% (v/v) glycerol, 0.3 M NaCl, and 1 mM phenylmethylsulfonyl fluoride) containing 10 mM ␤-mercaptoethanol, 0.2% Tween 20, 20 g/ml DNase I, 5 mM MgCl 2 , and 30 mg of lysozyme. Cell suspensions were incubated at 4°C for 1.5 h and then sonicated (Branson's Sonifier 450) on ice twice for 3 min at setting 10 with 10% duty cycle. Soluble protein fractions were recovered by centrifugation and loaded onto Talon (CLONTECH) beads previously equilibrated with buffer A. After washing with buffer A containing 15 mM imidazole, proteins were eluted with buffer A containing 0.15 M imidazole. The mut1-96 and mut65-256 samples were further purified for ITC experiments with DEAE column in the same way as human DREAM.
Preparation of Synthetic Oligonucleotides-Oligonucleotides used in this study represent DRE of human prodynorphin (DynDRE) and c-fos (c-fos DRE): DynDRE-1, 5Ј-GAAGCCGGAGTCAAGGAGGCCCCTG-3Ј; DynDRE-2, 5Ј-CAGGGGCCTCCTTGACTCCGGCTTC-3Ј; c-fos DRE-1, 5Ј-CTGCAGCGAGCAACTGAGAATCCAAGAC-3Ј; and c-fos DRE-2, 5Ј-GTCTTGGATTCTCAGTTGCTCGCTGCAG-3Ј. For ITC and dynamic light scattering (DLS) experiments, 10 mol of each oligonucleotide was synthesized on a DNA synthesizer by the solid phase phosphoramidate method and purified by fast protein liquid chromatography on a Zorbax oligonucleotide column (DuPont) using the volatile buffer containing 32 mM NaH 2 PO 4 (pH 7.0) and 20% (v/v) acetonitrile with an NaCl gradient. After lyophilization of the eluted fractions, the sample was dissolved with 2 ml of H 2 O and desalted using a PD-10 gel filtration column (Amersham Pharmacia Biotech). Desalted DNA was precipitated using EtOH/sodium acetate followed by evaporation of the solvent. Cy5 (Amersham Pharmacia Biotech) 5Ј-labeled oligonucleotides used for fluorescent EMSA were purchased from ACGT Corp. (Toronto, Canada). The same sequences of DynDRE-1 and DynDRE-2 mentioned above were used. For competition experiments, unlabeled double-stranded oligonucleotides of DynDRE, the canonical AP-1 from the collagenase gene (cAP-1), 5Ј-AAGCTTGCATGACTCAGACAG-3Ј, and mutated unlabeled double-stranded oligonucleotides of human DynDRE (DREmut5, 5Ј-GAAGCCGGAATCAAGGAGGCCCCTG-3Ј; DREmut4, 5Ј-GAAGCCGGAAACAAGGAGGCCCCTG-3Ј; mutation shown in bold) were used as unlabeled competitors (16) . Complementary strands were dissolved in annealing buffer (10 mM Tris-HCl, pH 7.4), completely denatured at 95°C, and annealed by slowly cooling to room temperature. Formation of double-stranded DNA was checked on a 20% nondenaturing polyacrylamide/0.25ϫ Tris-borate EDTA/1% (v/v) glycerol gel before binding reactions. The concentrations were determined via UV spectrometry.
Binding of 45 Ca 2ϩ -The binding of 45 Ca 2ϩ to DREAM was measured as the protein-bound radioactivity retained after ultrafiltration using a procedure described previously (17) . Briefly, DREAM (20 M) in 1.6 ml of 20 mM Tris (pH 7.4), 10 mM LDAO, and 1 mM DTT was placed in the sample compartment of a Centricon-10 concentrator (Millipore), and 20 l of 0.25 mM 45 CaCl 2 (1 Ci) was added as a radioactive tracer. The sample was subjected to centrifugation (at 2000 rpm) in a tabletop centrifuge (Beckman model TJ-6) at room temperature for 30 s, forming 20 l of filtrate. The radioactivity in the filtrate (free Ca 2ϩ ) and the radioactivity in an equal volume of the protein sample (total Ca 2ϩ ) were determined by liquid scintillation counting. Successive additions of nonradioactive Ca 2ϩ were made to the protein sample, and the abovementioned procedure was repeated. After each addition of nonradioactive ligand, the free Ca 2ϩ concentration was calculated from the measured radioactivity as follows:
where r a is the measured radioactivity of the filtrate, r b is radioactivity of protein sample, and Spectroscopic Analyses-Structural differences between the apo-and Ca 2ϩ -loaded form of DREAM and mut65-256 were investigated by CD spectroscopy and fluorescence spectroscopy. The protein concentration was 5-10 M dissolved in 10 mM Tris-HCl, pH 7.4, 1 mM DTT, and 1 mM EDTA for apo-DREAM. After the measurement for the apo-protein, the small amount of 1 M CaCl 2 solution was injected to the sample, giving a final Ca 2ϩ concentration of 5 mM for the Ca 2ϩ -loaded form. CD spectra were measured on a J-720 CD spectropolarimeter (JASCO) at 25°C. A cell path length of 1 mm was used. Each spectrum was collected with eight scans spanning wavelengths from 195 to 250 nm. Fluorescence spectra were recorded on a FluoroMax-2 fluorometer (Instruments S.A., Inc.). Excitation and emission were at 295 and 310 -440 nm, respectively. DLS-The molecular mass of DREAM was examined by DLS using DynaPro-MS (Protein Solutions) at 25°C. First, screening for a good condition to give a monomodal distribution was carried out using 30 -50 M DREAM in various buffers. 0.1 ml of each sample was centrifuged at 15,000 rpm for 30 min and passed through a filtering assembly containing a 0.1 m filter into a 12-l chamber quartz cuvette. At least 15 measurements were repeated. The data were analyzed using Dynamics 4.0 and DynaLS software as described by Moradian-Oldak et al. (18) . The samples for the experiments examining concentration dependence of the molecular mass were prepared by dilution of the protein stock solutions previously dialyzed against 10 mM Tris-HCl, pH 7.4, 10 mM LDAO, 1 mM DTT, and 1 mM EDTA or 5 mM CaCl 2 for apo-and Ca 2ϩ -DREAM, respectively. The samples diluted with the dialysis buffer were incubated overnight at 4°C before the DLS experiments.
Size Exclusion Chromatography-Determination of the molecular mass of the purified DREAM and mut65-256 in the Ca 2ϩ -bound and unbound form in solution was carried out on a Superdex 200 HR 10/30 column (Amersham Pharmacia Biotech) at 4°C in the buffers containing 20 mM Tris-HCl, pH 7.4, 10 mM LDAO, 1 mM DTT, and 5 mM CaCl 2 for Ca 2ϩ -DREAM or 1 mM EDTA for apo-DREAM. Separate aliquots (0.1 ml) of DREAM (8.7 and 87 M) and mut65-256 (87 M) were loaded onto the column and eluted at a flow rate of 0.4 ml/min. Apparent molecular masses were calculated using a standard curve of V e /V 0 versus the log of the molecular masses of standard proteins (␤-amylase, 200 kDa; alcohol dehydrogenase, 150 kDa; transferrin, 81 kDa; carbonic anhydrase, 29 kDa; and myoglobin, 17 kDa). V 0 is a void volume obtained using blue dextran (2000 kDa), and V e is a volume of elution.
ITC-Binding of DREAM to DynDRE and c-fos DRE was measured by ITC (19) using a MicroCal VP-ITC MicroCalorimeter (MicroCal Inc.). The protein and DNA samples were dialyzed against a buffer containing 10 mM Tris-HCl, pH 7.4, 10 mM LDAO, 1 mM DTT, and 5 mM CaCl 2 or 1 mM EDTA for the Ca 2ϩ -bound and unbound form, respectively. Experiments were performed at 35°C. A stock solution of DREAM (525-560 M) was titrated by injection of a total of 290 l of 15-25 M DNA in 29 aliquots. Heats of dilution were determined by titrating DREAM into the dialysis buffer and subtracted from the raw titration data before data analysis using MicroCal Origin version 5.0 provided by the manufacturer. Because the observed binding isotherm appeared multiphasic, the data were analyzed using a two-site binding model, resulting in the best fit of thermodynamic parameters to the titration. Binding of mut1-96 and mut65-256 to DynDRE was also measured in the same way.
Fluorescent EMSA-Proteins were exchanged firstly to 20 mM TrisHCl, pH 7.4, 10% (v/v) glycerol, 100 mM NaCl, 5 mM DTT, and 0.5 mM EDTA using PD-10 columns and concentrated to 115 M (mut1-70), 330 M (mut65-256), and 80 M (full length) by Centricon 3 or 10 (Millipore) at 4°C. Proteins were then incubated with 5 nM Cy5-labeled DNA for 5 h at room temperature in 10 mM HEPES, pH 7.9, 8 mM MgCl 2 , 0.1 mM EDTA, 2 mM DTT, and 0.005 unit/ml poly(dI-dC) (Amersham Pharmacia Biotech) with or without 10 mM CaCl 2 . Protein⅐DNA complexes were resolved in 5% nondenaturing polyacrylamide/0.25ϫ Tris-borate EDTA/1% (v/v) glycerol gels at 200 V for 30 min in 0.25ϫ Tris-borate EDTA and 0.5 mM MgCl 2 running buffer. Wet fluorescent gels were scanned using red fluorescence mode of a Storm 860 system (Molecular Dynamics) with a voltage setting of 1000 V and a scanning resolution of 200 m. For DNA competition experiments, a 15-fold excess of unlabeled double-stranded competitive oligonucleotides was added to competition assays of wild type or mut65-256, and a 65-fold excess of unlabeled DNA was added to the competition assays of mut1-70 1 h before further incubation with the labeled oligonucleotides.
RESULTS AND DISCUSSION

Ca
2ϩ Binding Studies-DREAM contains an N-terminal basic region (residues 1-65) and a C-terminal Ca 2ϩ -binding region (residues 70 -256) containing four EF-hand motifs that are similar in sequence to the Ca 2ϩ -binding sites found in calmod- ulin, troponin C, and recoverin. Like other members of the recoverin family ( Fig. 1) , the first EF-hand from the N terminus (EF-1) of DREAM contains substitutions (Cys-104 and Pro-105) that are expected to disrupt the structure of this binding loop and prevent Ca 2ϩ binding to EF-1, as seen in the crystal structures of recoverin (20) , neurocalcin (21) , and frequenin (22) . To determine whether this structural prediction is correct and to assess how many Ca 2ϩ ions bind to DREAM, direct measurements of Ca 2ϩ binding were performed. Equilibrium measurements of 45 Ca 2ϩ binding were conducted on DREAM (Fig. 2) . At saturation, three Ca 2ϩ ions bind to the protein, consistent with the view that EF-1 is disabled, whereas EF-2, EF-3, and EF-4 are functional. These three functional binding sites are also consistent with previous mutagenesis studies (9, 15) . The fractional saturation (Y), which can be obtained from the data, can be represented by the Hill equation:
where (Ca 2ϩ ) is the free Ca 2ϩ concentration, K d is the apparent dissociation constant, and a denotes the Hill coefficient. From the analysis of the Ca 2ϩ binding data (Fig. 2) , DREAM binds three Ca 2ϩ ions with a dissociation constant of 14 M and a Hill coefficient value of 0.7. The Hill slope (Ͻ1.0) and multiphasic Scatchard plot (data not shown) suggest heterogeneous binding of Ca 2ϩ and that the three binding sites may have markedly different intrinsic affinities. If the three sites are independent, then the fractional saturation expression simplifies to
where K EF2 represents the dissociation constant for EF-2, and so forth. nounced upon the addition of Ca 2ϩ , suggesting that Ca 2ϩ binding causes a slight increase in the helical content of DREAM and rearrangement of preexisting EF-hand helices relative to each other, similar to that found in other known EF-hand proteins (24) .
The intrinsic tryptophan fluorescence spectra of full-length DREAM and an N-terminal deletion mutant of mouse DREAM (residues 65-256, mut65-256) are presented in Fig. 3 . The full-length DREAM protein contains three tryptophan residues (Trp-32, Trp-50, and Trp-169), whereas mut65-256 has only Trp-169. The fluorescence emission of tryptophan in these spectra is very sensitive to its surrounding chemical environment and hence provides an effective probe of structural changes in the protein (25) .
The fluorescence emission spectrum of mut65-256 in the absence of Ca 2ϩ exhibits an emission maximum at 345 nm, which is shifted to 340 nm upon the addition of saturating amounts of Ca 2ϩ . This blue shift in the spectrum indicates a Ca 2ϩ -induced structural change in the protein that causes Trp-169 to reside in a more hydrophobic environment in the Ca 2ϩ -bound protein.
The fluorescence spectrum of the full-length protein exhibits an emission intensity maximum at 347 nm in the absence of Ca 2ϩ , whereas the emission maximum is shifted less than 2 nm upon Ca 2ϩ binding to DREAM. These spectra represent the average emission from three tryptophan residues (Trp-32, Trp-50, and Trp-169). Taking into account the Ca 2ϩ -induced blue shift of Trp-169 (Fig. 3) , the emission from Trp-32 and/or Trp-50 must therefore undergo a Ca 2ϩ -induced red shift, suggesting that Trp-32 and/or Trp-50 may occupy a more polar environment in the Ca 2ϩ -bound state. Thus, Ca 2ϩ binding may promote an allosteric structural change in the N-terminal region that may increase the solvent accessibility of Trp-32 and/or Trp-50. This change in solvent accessibility may be explained in part by the Ca 2ϩ -induced change in oligomerization state of DREAM as described below.
Oligomerization of DREAM-Initial DLS studies performed on DREAM (in the absence of detergent) indicated a very broad distribution of hydrodynamic radii, suggesting that the protein solution was polydisperse due to the formation of heterogeneously aggregated species. An extensive screening of various solvent conditions (pH, ionic strength, and detergent) was performed using 50 -100 M DREAM. The addition of detergent (10 mM LDAO) with low salt concentration (Ͻ20 mM KCl) at pH 7-8 resulted in a protein solution with a monomodal distribution of the molecular mass of DREAM without any aggregation. These conditions were subsequently used throughout this study.
DLS experiments performed at a variety of protein concentrations were carried out on both apo-DREAM and Ca 2ϩ -DREAM. Because the DLS data included light scattering contributions from both protein and the LDAO micelles, a multidispersive model was applied in DynaLS software to fit the observed DLS data at a resolution of 1.0. This analysis enabled the light scattering contribution from the DREAM protein (hydrodynamic radius of 4 -5 nm) to be completely resolved from the scattering that corresponded to the LDAO micelle size (hydrodynamic radius of 2.0 nm). Hence, the multidispersive analysis enabled us to accurately extract the size of the protein in the presence of detergent. Table I summarizes our analysis of the DLS data. The hydrodynamic radius (R H ) of apo-DREAM was measured to be 4.45-4.65 nm at protein concentrations of 17-450 M. The molecular mass of apo-DREAM was then calculated based on R H to be 108 -120 kDa, assuming a spherical molecular shape. The R H value of Ca 2ϩ -DREAM was 3.60 nm at dilute protein concentrations and increased to 4.65-4.72 nm at protein concentrations greater than 200 M. The molecular mass of Ca 2ϩ -DREAM was calculated from R H to be 64.7 kDa at dilute protein concentrations (17-150 M) and 120 kDa at protein concentrations greater than 200 M. These molecular mass determinations and their protein concentration dependence indicate that apo-DREAM exists as a tetramer, whereas Ca 2ϩ -DREAM is a dimer at protein concentrations less than 150 M and forms a tetramer at protein concentrations higher than 200 M. The molecular mass of DREAM was also confirmed by size exclusion chromatography. The apo-DREAM at an initial concentration of 87 M eluted in a single peak with a relative elution volume V e /V 0 ϭ 1.55 (Fig. 4A ), calibrated to a molecular mass of 107 kDa (Fig. 4D) . In contrast, the Ca 2ϩ -bound protein exhibited a much longer elution time (V e /V 0 ϭ 1.73), calibrated to a molecular mass of 55 kDa (Fig. 4D) . At a more dilute protein concentration (8.7 M), apo-DREAM showed a very broad elution pattern (Fig. 4B) . A partially resolved peak (V e /V 0 ϭ 1.58) representing the tetramer species was flanked by shoulder peaks corresponding to dimer and monomer species. In contrast, the dilute Ca 2ϩ -DREAM eluted in a single peak corresponding to dimer (V e /V 0 ϭ 1.73 and molecular mass ϭ 55 kDa).
Similar Ca 2ϩ -induced changes in molecular mass and oligomerization state were also observed for a C-terminal fragment of mouse DREAM (residues 65-256, mut 65-256) containing only the four EF-hand Ca 2ϩ -binding sites. The DLS analysis indicated that apo-mut65-256 forms a tetramer (R H ϭ 4.23 nm; molecular mass ϭ 95.6 kDa), whereas Ca 2ϩ -bound mut65-256 forms a dimer (R H ϭ 3.13 nm; molecular mass ϭ 46.1 kDa). In addition, the size exclusion chromatography results on mut65-256 are consistent with the DLS analysis and indicate that mut65-256 forms a tetramer (V e /V 0 ϭ 1.58; molecular mass ϭ 94 kDa) and dimer (V e /V 0 ϭ 1.82; molecular mass ϭ 39 kDa) in the apo-and Ca 2ϩ -loaded states, respectively (Fig. 4C) . Therefore, the C-terminal Ca 2ϩ -binding region must be responsible for the oligomerization of DREAM.
In summary, apo-DREAM has a propensity to form a tetramer at protein concentrations higher than 20 M. The Ca 2ϩ -bound DREAM forms a stable dimer at low protein concentrations and forms a tetramer at concentrations higher than 200 M. The dramatically different hydrodynamic properties observed here for the Ca 2ϩ -free and Ca 2ϩ -bound forms of DREAM may also be due, in part, to possible Ca 2ϩ -induced changes in molecular shape. However, the sharp dependence of the DLS and size exclusion chromatography data on protein concentration (Table I and Fig. 4B) indicates that the observed hydrodynamic changes of the protein are also the result of protein oligomerization. Very similar Ca 2ϩ -dependent oligomerization properties were observed for the C-terminal fragment, mut65-256. Hence, Ca 2ϩ -induced structural changes in the C-terminal EF-hand region may be crucial for the alteration of its oligomerization state. Other recoverin-like proteins are also known to exhibit Ca 2ϩ -regulated dimerization. For example, neurocalcin forms a dimer in the Ca 2ϩ -bound state (21), whereas Ca 2ϩ -free neurocalcin is monomeric (26) . Conversely, guanylate cyclase-activating protein-2 forms a dimer only in the Ca 2ϩ -free state and is monomeric in the Ca 2ϩ -bound state (26) . DNA Binding Studies-DREAM was reported to suppress the expression of human prodynorphin and c-fos genes by binding to their DRE (9) . The c-fos DRE sequence has high similarity to the reverse sequence of DynDRE, and EMSA previously showed that three DREs of DynDRE, c-fos DRE, and reversed DynDRE have comparable affinity to apo-DREAM (9, 15) . We applied ITC to quantitatively investigate the energetics of DREAM binding to the duplexes of DNA oligonucleotides corresponding to the DRE sequence of prodynorphin and c-fos. All ITC experiments were carried out using 10 mM LDAO detergent and a salt concentration less than 10 mM. These solvent conditions were necessary to achieve reproducible detection of heat exchange in the titration.
The apo-DREAM protein exhibited endothermic binding to DynDRE, as indicated by a relatively large and positive enthalpy of binding (ϩ25 kcal/mol) observed in the calorimetric titration (Fig. 5, A and B) . In contrast, very little enthalpy (Ͻ4 kcal/mol) was observed in the titration of Ca 2ϩ -DREAM with DynDRE (data not shown). Thus, apo-DREAM is the more active form of the protein that binds to DynDRE, and Ca 2ϩ -DREAM does not exhibit any appreciable binding. The positive heat of formation of the apo-DREAM⅐DRE complex (Fig. 5, A  and B) indicates that this interaction is an enthalpically unfavorable (entropically driven) process that may include desolvation of water molecules and/or conformational changes induced by DRE binding. Other DNA-binding proteins such as the TATA-binding protein (27) , nuclear hormone receptors (28) , and the Cro repressor (29) also exhibit similar entropically dominated binding to DNA.
The stoichiometry of DRE binding was also determined from our analysis of the calorimetry data. Analysis using a one-site model indicated that one molecule of DRE was bound to each DREAM polypeptide. Because apo-DREAM forms a tetramer as described above, the observed stoichiometry of 1 indicates that each DREAM tetramer contains four DNA binding sites.
The complexation of a DREAM tetramer with four molecules of DNA was also confirmed by DLS, which gave a molecular mass of 200 -230 kDa corresponding to a DREAM tetramer (120 kDa) bound to four molecules of DRE (18 kDa ϫ 4) ( Table I) .
To minimize protein aggregation and more accurately dissect DRE binding energetics, a reverse calorimetric titration was performed in which aliquots of apo-DREAM in the syringe were sequentially injected into the sample cell containing DynDRE (Fig. 5A) . The observed isotherm in this case is multiphasic and must be deconvoluted using a model with multiple binding sites (Fig. 5B) . The ITC data for the reverse titration were best fit using a two-site model whose thermodynamic parameters are listed in Table II . The first site in this model has a much higher affinity (K 1 ϭ 1.3 ϫ 10 7 M Ϫ1 ) and larger enthalpy (n 1 ϫ ⌬H 1 0 ϭ 24 kcal/mol) than those of the other site (K 2 ϭ 1.6 ϫ 10 6 M Ϫ1 and n 2 ϫ ⌬H 2 0 ϭ 0.8 kcal/mol). The stoichiometry of the high and low affinity sites are 0.25 and 0.75 mole protein/mole DRE, respectively. A plausible interpretation would be that a preformed apo-DREAM tetramer binds one DNA molecule with markedly higher affinity than that of the other three molecules of DNA. The electrostatic repulsion created by the binding of multiple DNA molecules to one DREAM tetramer might explain the apparent anticooperativity of DNA binding, giving rise to the high and low affinity sites. The single high affinity site on an apo-DREAM tetramer is likely to be biologically more relevant because the DREAM tetramer concentration should Table II. be much higher than that of DRE in the cell nucleus. Under these conditions, the DRE binding would be limited primarily to the high affinity site on the DREAM tetramer.
The binding of c-fos DRE to apo-DREAM and the energetics of this interaction were found to be very similar to what we had measured for the DynDRE interaction (Fig. 5, A and B ; Table  II ). The binding isotherm (data not shown) was biphasic and fit using a two-site model (Table II) . The affinity of the first site for c-fos DRE (K 1 ϭ 4 ϫ 10 6 M Ϫ1 ) is slightly lower than that of DynDRE. The other binding parameters for c-fos DRE are nearly identical to those of DynDRE. The three-dimensional structures of the protein⅐DNA complexes are needed to understand how apo-DREAM recognizes these different DNA sequences.
Localization of the DNA Binding Site-To attempt to localize the DNA-binding region in DREAM, we made a series of deletion mutants of mouse DREAM (91% identical to human calsenilin/DREAM, see Fig. 1 ), which are defined as mut1-70 (residues 1-70), mut1-96 (residues 1-96), and mut65-256 (residues 65-256). These protein fragments were tested for their ability to bind the DRE using EMSA (Fig. 6 ) and ITC. Only the Ca 2ϩ -free forms of the full-length protein and mut65-256 show sequence-specific binding to DynDRE, whereas the Ca 2ϩ -bound forms do not exhibit any detectable binding. Interestingly, mut1-70 and mut1-96 appear to bind to DynDRE regardless of Ca 2ϩ and do not exhibit sequence specificity (Fig.  6, B and E) . Thus, the DNA-binding region appears to include residues from both the N-terminal basic and C-terminal Ca 2ϩ -binding regions.
ITC studies were carried out on the deletion mutants to quantify and evaluate the energetics of DNA binding to the N-terminal (mut1-96) and C-terminal Ca 2ϩ -binding (mut65-256) regions (note that mut1-70 protein could not be obtained in high enough quantities to be studied by ITC). Titration of mut1-96 to DRE yielded a detectable amount of heat exchange (ϳ4 -5 kcal/mol) regardless of the Ca 2ϩ concentration, indicating that the mut1-96 protein binds to DRE (data not shown). The amount of heat exchange here is quite small and is comparable to the very slight enthalpy of DRE binding observed for the Ca 2ϩ -bound full-length DREAM (data not shown). Thus, the very weak DRE binding to Ca 2ϩ -bound DREAM detected by ITC may be due to an exposed N-terminal basic region that weakly binds the DRE.
The ITC isotherm of apo-mut65-256 titration into DynDRE is shown in Fig. 5 , C and D, and the thermodynamic parameters are summarized in Table II 
is larger than that of mut65-256 (12 kcal/mol). The lower total enthalpy for mut65-256 could also be explained by a lack of enthalpy contributed from the N-terminal basic region (residues 1-65), which is further evidence that the N-terminal region does indeed contribute to DRE binding. Correspondingly, the full-length protein binds DRE with 2-fold higher apparent affinity compared with that of mut65-256.
Although the N-terminal region does contribute to the energetics of DRE binding, the biological significance of the Nterminal region remains uncertain. The thermodynamics of DRE binding to the functional, high affinity site of mut65-256 is very similar to that of the full-length protein (Table II) . Also, like the full-length protein, mut65-256 forms a tetramer in the Ca 2ϩ -free state that dissociates into dimers in the Ca 2ϩ -bound state. Hence, it would seem that mut65-256 possesses all the essential features to serve as a Ca 2ϩ -regulated transcriptional repressor. Consistent with this view is the recent report that DREAM has a caspase-3 cleavage site at residues Asp-61-Asp-64 located between the N-terminal basic region and the C-terminal Ca 2ϩ -binding region (12) . The data obtained here suggest that DREAM may function as a transcriptional repressor even after cleavage by caspase-3.
Mechanism of Ca 2ϩ -regulated DNA Binding to DREAM-In this study, we demonstrate that Ca 2ϩ -free DREAM forms a tetramer in the protein⅐DNA complex, whereas the Ca 2ϩ -bound protein forms a dimer under physiological conditions and does not bind appreciably to DNA. The N-terminal region (mut1-70 and mut1-96) contributes somewhat to the energetics of DNA binding, and the C-terminal region (mut65-256) exhibits Ca 2ϩ -regulated oligomerization and DNA binding akin to that of the full-length protein. As a result, the DNA-binding site may consist of contacts made by residues from both the N-terminal and C-terminal regions. However, the N-terminal region does not appear to be essential for the Ca 2ϩ -regulated oligomerization. In addition, we measured a binding stoichiometry of four DNA molecules bound to one DREAM tetramer. These results suggest two possible modes of Ca 2ϩ -regulated DNA binding. Each polypeptide subunit of the tetramer could contain an individual DNA-binding site that may be altered by Ca 2ϩ -induced structural changes within each subunit. Alternatively, the DNA-binding sites could be integrally generated by tetramer formation, in which case the sites might be disassembled by Ca 2ϩ -induced dissociation of the tetramer. The observed anticooperativity of DNA binding suggests that the four DNAbinding sites are coupled and might be spatially close to one another. Clearly, the three-dimensional atomic resolution structure of the DREAM tetramer bound to DNA will need to be determined to more fully understand the precise mechanism of Ca 2ϩ -regulated DNA binding. Conclusion-The recombinant form of calsenilin/DREAM/ KChIP3 was expressed, purified, and characterized using several physicochemical methods. Our light scattering and calorimetry studies reveal that a preformed tetramer of apo-DREAM binds four molecules of DRE. The binding of three Ca 2ϩ ions to each DREAM polypeptide subunit causes the tetrameric protein to dissociate into dimers and may disrupt the Ca 2ϩ -bound protein from binding to DNA. One DRE molecule binds to an apo-DREAM tetramer with high affinity (K d ϭ 75 nM), and the other three DRE molecules bind with markedly lower affinity (K d ϭ 700 nM), presumably due to anticooperativity. We suggest that the single site with highest affinity may be biologically most important because the DREAM tetramer concentration in the cell nucleus is likely to be much higher than the DRE concentration. Hence, there may not be enough DRE molecules in the cell nucleus to fill the low affinity sites. The tetramer of DREAM bound to only one DNA element may be structurally unique as a transcriptional regulator complex.
Our results suggest that the DNA-binding sites on DREAM appear delocalized and may consist of residues from both the N-terminal and C-terminal regions. Therefore, we suggest that Ca 2ϩ -induced structural changes within the EF-hand motifs observed in this study lead to the dissociation of the tetrameric protein into dimers, which in turn may alter the DNA-binding sites. Our next goal is to further elucidate and more rigorously analyze the Ca 2ϩ -regulated DNA binding by DREAM by determining the atomic resolution three-dimensional structure of the protein⅐DNA complex.
